Despite strong revenue, the company's high P/S ratio and weaker forecasted growth may concern investors. High share prices may not be sustainable with expected revenue growth. Business prospects may not significantly improve, posing a risk to share price.

Investor caution is advised as Suzhou Zelgen Biopharmaceuticals' high P/S and less than stellar revenue forecasts could indicate a potential downturn in share price.

The substantial downgrade in this year's forecasts casts caution over Suzhou Zelgen Biopharmaceuticals with slower than industry growth expected.